Table 3.
Limitations of Biomarkers for AD
| 1. Majority of studies performed in select research populations |
| 2. Lack of validation in autopsy studies |
| 3. Lack of data for follow up past 1-2 years |
| 4. Difficulty in collecting, processing and interpreting CSF biomarker data |
| 5. Non-specificity of biomarkers |
| 6. Precise temporal evolution of biomarkers not known |